Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Core Insights - Q32 Bio Inc. has initiated dosing for the first patients in both Part A open-label extension and Part B of the SIGNAL-AA Phase 2a clinical trial for bempikibart, targeting alopecia areata [1][2] - The company reports encouraging clinical activity from Part A, with significant improvements in SALT scores and sustained responses observed in patients up to 55 weeks post-treatment [2][3] - Part B of the trial will involve approximately 20 patients over 36 weeks, with topline data expected in the first half of 2026 [3] Company Overview - Q32 Bio is a clinical stage biotechnology company focused on innovative therapies for alopecia areata and other autoimmune diseases, with an estimated 700,000 individuals affected in the U.S. [4] - The company is advancing bempikibart, a fully human anti-IL-7Rα antibody, which aims to re-regulate adaptive immune function [4] Clinical Trial Details - Part A of the SIGNAL-AA trial was a randomized, double-blind, placebo-controlled study that demonstrated significant clinical activity in patients with severe alopecia areata [2][3] - Part B will evaluate the efficacy of bempikibart based on mean percentage change in SALT scores and the proportion of subjects achieving specific SALT improvements [3]